{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:10:36Z","timestamp":1791821436219,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ijcha.2024.101358","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:14:35Z","timestamp":1707524075000},"page":"101358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation"],"prefix":"10.1016","volume":"51","author":[{"given":"Josep","family":"Com\u00edn Colet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Sicras Mainar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Salazar-Mendiguch\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Isabel del Campo Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Echeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vilanova Larena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Delgado S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcha.2024.101358_b0005","doi-asserted-by":"crossref","first-page":"e000100","DOI":"10.1161\/HCQ.0000000000000100","article-title":"2020 Update to the 2016 ACC\/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"14","author":"Heidenreich","year":"2021","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101358_b0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101358_b0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.recesp.2013.07.015","article-title":"Prevalencia de fibrilaci\u00f3n auricular en Espa\u00f1a. Resultados del estudio OFRECE","volume":"67","author":"G\u00f3mez-Doblas","year":"2014","journal-title":"Rev. Esp. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101358_b0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semerg.2018.10.005","article-title":"Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain","volume":"45","author":"Polo Garcia","year":"2019","journal-title":"Semergen"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101358_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rccar.2016.03.021","article-title":"Prevalencia de fibrilaci\u00f3n auricular y caracter\u00edsticas de la fibrilaci\u00f3n auricular no valvular en la poblaci\u00f3n general","volume":"24","author":"Mora-Llabata","year":"2017","journal-title":"Registro AFINVA. Revista Colombiana De Cardiolog\u00eda."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101358_b0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10557-020-06981-3","article-title":"Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients","volume":"34","author":"Schafer","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.ijcha.2024.101358_b0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/joim.12468","article-title":"A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation","volume":"279","author":"Lip","year":"2016","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101358_b0040","doi-asserted-by":"crossref","first-page":"e0231565","DOI":"10.1371\/journal.pone.0231565","article-title":"A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study","volume":"15","author":"Escobar","year":"2020","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.ijcha.2024.101358_b0045","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"J. Am. Med. Assoc."},{"issue":"14","key":"10.1016\/j.ijcha.2024.101358_b0050","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2217\/cer-2019-0079","article-title":"Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study","volume":"8","author":"Ramagopalan","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.ijcha.2024.101358_b0055","article-title":"Real-world data of anticoagulant treatment in non-valvular atrial fibrillation","volume":"8","author":"Calderon","year":"2021","journal-title":"Front Cardiovasc Med."},{"issue":"7","key":"10.1016\/j.ijcha.2024.101358_b0060","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/STROKEAHA.120.028825","article-title":"Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study","volume":"51","author":"Van Ganse","year":"2020","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.ijcha.2024.101358_b0065","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1055\/s-0040-1713889","article-title":"Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review","volume":"120","author":"de Vries","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"9921","key":"10.1016\/j.ijcha.2024.101358_b0070","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2024.101358_b0075","unstructured":"European Medicines Agency (EMA), Assessment report. Remdesivir. Published online 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/veklury-epar-public-assessment-report_en.pdf. (Accessed: September, 2020)."},{"key":"10.1016\/j.ijcha.2024.101358_b0080","article-title":"COVID-19. Las consecuencias sociales, sanitarias y cardiovasculares","author":"Fillat","year":"2020201","journal-title":"Revista Espa\u00f1ola De Cardiolog\u00eda Suplementos."},{"issue":"11","key":"10.1016\/j.ijcha.2024.101358_b0085","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.recesp.2020.06.027","article-title":"Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology","volume":"73","author":"Barrios","year":"2020","journal-title":"Rev Esp Cardiol (engl Ed)"},{"issue":"14","key":"10.1016\/j.ijcha.2024.101358_b0090","doi-asserted-by":"crossref","first-page":"e017529","DOI":"10.1161\/JAHA.120.017529","article-title":"Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019","volume":"9","author":"Rattanawong","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"15","key":"10.1016\/j.ijcha.2024.101358_b0095","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/eurjpc\/zwab021","article-title":"Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?","volume":"29","author":"Papakonstantinou","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101358_b0100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3389\/fphar.2020.01275","article-title":"Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101358_b0105","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Big-Pac. 20Available from: http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=29236. (Accessed: 13 April, 2021)."},{"key":"10.1016\/j.ijcha.2024.101358_b0110","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"Pmu146 Validation and Representativeness of the Spanish Big-Pac Database: Integrated Computerized Medical Records for Research into Epidemiology, Medicines and Health Resource Use (Real Word Evidence)","volume":"22","author":"Sicras-Mainar","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.ijcha.2024.101358_b0115","unstructured":"Bolet\u00edn Oficial del Estado. Ley Org\u00e1nica 3\/2018, de 5 de Diciembre, de Protecci\u00f3n de Datos Personales y Garant\u00eda de Los Derechos Digitales. Vol 294. 2018:119788-119857. Available from: https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2018-16673. (Accessed: 31 August, April)."},{"key":"10.1016\/j.ijcha.2024.101358_b0120","unstructured":"Ministerio de Sanidad CyBS. International Classification of Diseases (ICD) 2020. Available from: https:\/\/eciemaps.mscbs.gob.es\/ecieMaps\/browser\/metabuscador.html. (Accessed: 31 August, 2021)."},{"key":"10.1016\/j.ijcha.2024.101358_b0125","unstructured":"World Health Organization (WHO). The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD). Available from: https:\/\/www.who.int\/standards\/classifications\/other-classifications\/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses. (Accessed: 8 April, 2021)."},{"key":"10.1016\/j.ijcha.2024.101358_b0130","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular no valvular 2016:11. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/criterios-anticoagulantes-orales.pdf. (Accessed: 10 January, 2024)."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101358_b0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.ijcha.2024.101358_b0140","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/clc.22294","article-title":"Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2 -VASc, R2 CHADS2, HAS-BLED, ATRIA, and more)","volume":"37","author":"Dzeshka","year":"2014","journal-title":"Clin. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcha.2024.101358_b0145","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s11739-020-02439-4","article-title":"Thrombosis centres and AVKs monitoring in COVID-19 pandemic","volume":"15","author":"Barcellona","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ijcha.2024.101358_b0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2020.11.004","article-title":"Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic","volume":"197","author":"Patel","year":"2021","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.ijcha.2024.101358_b0155","doi-asserted-by":"crossref","first-page":"e001784","DOI":"10.1136\/openhrt-2021-001784","article-title":"OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic","volume":"8","author":"Open","year":"2021","journal-title":"Open Heart."},{"key":"10.1016\/j.ijcha.2024.101358_b0160","unstructured":"NHS England and NHS Improvement. Clinical guide for the management of anticoagulant services during the coronavirus pandemic 2020. Available from: https:\/\/www.nice.org.uk\/media\/default\/about\/covid-19\/specialty-guides\/specialty-guide-anticoagulant-services-and-coronavirus.pdf. (Accessed: 10 January, 2024)."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101358_b0165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.recesp.2020.04.006","article-title":"Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology","volume":"73","author":"Vivas","year":"2020","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"10.1016\/j.ijcha.2024.101358_b0170","unstructured":"Ministerio de Sanidad. Manejo cl\u00ednico del COVID-19: tratamiento m\u00e9dico 2020. Available from: https:\/\/www.semg.es\/images\/2020\/Coronavirus\/20200319_Protocolo_manejo_clinico_tto_COVID-19.pdf. (Accessed: 10 November, 2021)."},{"key":"10.1016\/j.ijcha.2024.101358_b0175","unstructured":"European Centre for Disease Prevention and Control. Infection prevention and control and preparedness for COVID-19 in healthcare settings. Second Update 2020. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Infection-prevention-control-for-the-care-of-patients-with-2019-nCoV-healthcare-settings_update-31-March-2020.pdf. (Accessed: 10 January, 2024)."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:13:55Z","timestamp":1762492435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"alternative-id":["S2352906724000241"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101358","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101358"}}